We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00126854
First Posted: August 5, 2005
Last Update Posted: February 25, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta
August 3, 2005
August 5, 2005
February 25, 2016
October 2005
April 2011   (Final data collection date for primary outcome measure)
pilot study meant to establish scanning parameters on 3T MRSI
Same as current
Complete list of historical versions of study NCT00126854 on ClinicalTrials.gov Archive Site
safety/toxicity
Same as current
Not Provided
Not Provided
 
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation
The purpose of this study is to establish the correct scanning parameters for obtaining good quality 3 Tesla (3T) magnetic resonance spectroscopy images (MRSI) of the prostate gland before and after brachytherapy implantation for prostate cancer. Three Tesla MRSI may be a valuable additional diagnostic and follow-up investigation for prostate cancer patients.
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Prostatic Neoplasm
Procedure: Magnetic Resonance Spectroscopy Imaging
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
April 2011
April 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Suitable candidate for prostate brachytherapy to treat prostate cancer
  • Patient signs a study consent form

Exclusion Criteria:

  • Have received other radiotherapy for prostate cancer or hormone treatments
  • Has contraindication to MRSI scanning
  • Does not sign study consent form
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00126854
NA-15-0003 / 22011
No
Not Provided
Not Provided
AHS Cancer Control Alberta
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Don Yee, MD AHS Cancer Control Alberta
AHS Cancer Control Alberta
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP